Moreover, SJB3-019A triggers synergistic anti-MM activity when combined with other anti-MM agents, such as bortezomib, ACY1215 (an HDAC6 inhibitor), lenalidomide, or pomalidomide [189]. The gene discussed is HDAC6; the disease is Miyoshi myopathy.